JPH0524339Y2 - - Google Patents
Info
- Publication number
- JPH0524339Y2 JPH0524339Y2 JP12386290U JP12386290U JPH0524339Y2 JP H0524339 Y2 JPH0524339 Y2 JP H0524339Y2 JP 12386290 U JP12386290 U JP 12386290U JP 12386290 U JP12386290 U JP 12386290U JP H0524339 Y2 JPH0524339 Y2 JP H0524339Y2
- Authority
- JP
- Japan
- Prior art keywords
- serum creatinine
- value
- age
- window
- creatinine value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 140
- 229940109239 creatinine Drugs 0.000 claims description 70
- 210000002966 serum Anatomy 0.000 claims description 59
- 239000003814 drug Substances 0.000 claims description 33
- 229940079593 drug Drugs 0.000 claims description 30
- 230000037396 body weight Effects 0.000 claims description 8
- 230000003907 kidney function Effects 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 230000007423 decrease Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12386290U JPH0524339Y2 (enExample) | 1990-10-22 | 1990-11-26 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11034190 | 1990-10-22 | ||
| JP12386290U JPH0524339Y2 (enExample) | 1990-10-22 | 1990-11-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0488943U JPH0488943U (enExample) | 1992-08-03 |
| JPH0524339Y2 true JPH0524339Y2 (enExample) | 1993-06-21 |
Family
ID=31948845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12386290U Expired - Lifetime JPH0524339Y2 (enExample) | 1990-10-22 | 1990-11-26 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0524339Y2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6394997B2 (ja) * | 2016-01-09 | 2018-09-26 | 国立大学法人 熊本大学 | 調剤業務支援を目的とした薬剤監査プログラムならびに薬剤監査システム |
-
1990
- 1990-11-26 JP JP12386290U patent/JPH0524339Y2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0488943U (enExample) | 1992-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5776783A (en) | Method of monitoring therapeutic agent consumption | |
| Liukas et al. | Pharmacokinetics of intravenous paracetamol in elderly patients | |
| Giardina et al. | Metabolism of procainamide in normal and cardiac subjects | |
| Baber et al. | The interaction between indomethacin and probenecid; A clinical and pharmacokinetic study | |
| Chiang et al. | Recreational nitrous oxide abuse-induced vitamin B12 deficiency in a patient presenting with hyperpigmentation of the skin | |
| Gibaldi et al. | Pharmacokinetics in clinical practice: 2. Applications | |
| Koren et al. | A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn | |
| Tobin et al. | The management of urinary incontinence in local authority residential homes for the elderly | |
| Southwood et al. | Concepts in clinical pharmacokinetics | |
| Jalali et al. | Generic drug and bioequivalence studies | |
| Finkelstein et al. | Pharmacokinetics of digoxin and digitoxin in patients undergoing hemodialysis | |
| Tremoulet et al. | Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and-infected infants | |
| Carasco et al. | Review of commonly used age‐based weight estimates for paediatric drug dosing in relation to the pharmacokinetic properties of resuscitation drugs | |
| PREIBISZ et al. | Digoxin tablet bioavailability: single-dose and steady-state assessment | |
| JPH0524339Y2 (enExample) | ||
| Fleckenstein et al. | Assessment of the biologic availability of digoxin in man | |
| Chrymko et al. | Creatinine clearance predictions in acutely ill patients | |
| Shanks et al. | Clinical comparison of two electronic spirometers with a water-sealed spirometer | |
| McNair et al. | Differential sensitivity of two palmar sweat measures | |
| Rockland et al. | Effects of trihexyphenidyl on plasma chlorpromazine in young schizophrenics | |
| MacIntyre | Prescribing medicines for patients with renal impairment | |
| Vesell et al. | Reproducibility of antipyrine half‐lives in elderly subjects | |
| Young et al. | Pharmacokinetics of aminoglycosides in patients with chronic spinal cord injury | |
| Nahata | Progress in pediatric drug therapy | |
| Higbee | The geriatric patient: general physiologic and pharmacologic considerations |